Literature DB >> 12093716

Gamma hydroxybutyric acid (GHB) intoxication.

Phillip E Mason1, William P Kerns.   

Abstract

Gamma hydroxybutyric acid (GHB) is a naturally occurring analog of gamma-aminobutyric acid (GABA) that has been used in research and clinical medicine for many years. In the past decade it has become very popular as a dietary supplement and recreational drug. Acute overdose leads to profound alteration of mental status and variable amounts of respiratory depression. With proper management, most patients recover fully within six hours. However, respiratory arrest and death have been reported in severe GHB intoxication. In addition to acute overdose, there is a GHB withdrawal syndrome that is similar to sedative/hypnotic and ethanol withdrawal. Recently several congeners of GHB, gamma butyrolactone and 1,4-butanediol, have emerged as drugs of abuse and show toxidromes similar to GHB. Emergency physicians should be familiar with the presentation and management of GHB-related emergencies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093716     DOI: 10.1111/j.1553-2712.2002.tb02154.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  26 in total

Review 1.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

2.  Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acid.

Authors:  Melanie A Felmlee; Samuel A Roiko; Bridget L Morse; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2010-03-09       Impact factor: 4.030

3.  Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study.

Authors:  Marilyn E Morris; Bridget L Morse; Gloria J Baciewicz; Matthew M Tessena; Nicole M Acquisto; David J Hutchinson; Robert Dicenzo
Journal:  J Clin Toxicol       Date:  2011-11-10

4.  A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose.

Authors:  Nisha Vijay; Bridget L Morse; Marilyn E Morris
Journal:  Pharm Res       Date:  2014-12-06       Impact factor: 4.200

Review 5.  Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.

Authors:  Lawrence P Carter; Daniel Pardi; Jane Gorsline; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-06-02       Impact factor: 4.492

6.  Brain extracellular γ-hydroxybutyrate concentrations are decreased by L-lactate in rats: role in the treatment of overdoses.

Authors:  Samuel A Roiko; Nisha Vijay; Melanie A Felmlee; Marilyn E Morris
Journal:  Pharm Res       Date:  2013-01-15       Impact factor: 4.200

7.  The drug of abuse gamma-hydroxybutyrate is a substrate for sodium-coupled monocarboxylate transporter (SMCT) 1 (SLC5A8): characterization of SMCT-mediated uptake and inhibition.

Authors:  Dapeng Cui; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2009-04-23       Impact factor: 3.922

8.  An investigation of flumazenil to antagonize gamma-hydroxybutyrate intoxication in a murine model.

Authors:  David C Lee; Wayne A Satz; Timothy Dougherty; Tucker Greene
Journal:  J Med Toxicol       Date:  2006-06

9.  Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative effects of the drug of abuse, γ-hydroxybutyric acid.

Authors:  Nisha Vijay; Marilyn E Morris
Journal:  J Pharm Sci       Date:  2014-08-29       Impact factor: 3.534

10.  Endogenous gamma-hydroxybutyric acid (GHB) concentrations in post-mortem specimens and further recommendation for interpretative cut-offs.

Authors:  Hilke Andresen-Streichert; P Jensen; J Kietzerow; M Schrot; N Wilke; E Vettorazzi; A Mueller; S Iwersen-Bergmann
Journal:  Int J Legal Med       Date:  2014-08-02       Impact factor: 2.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.